**Supplemental Table 1: Method Comparison Summary for the TEG® 6s vs. TEG® 5000** **Hemostasis Analyzers**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Assay** | **N** | **Spike** | **Slope**  **ß [95% CI]** | **Correlation ƿ [95% CI]** | **Correlation p-value** | **AMR Point 1** | **AMR Bias 1** | **AMR Point 2** | **AMR Bias 2** | **NRR Point 1** | **Bias at NRR Point 1** | **NRR Point 2** | **Ref Bias 2** |
| CFF.MA | 450 | 30 | 1.21  [1.18, 1.25] | 0.95  [0.94, 0.96] | <0.001 | 4 | -2.01  [-2.77, -1.23] | 52 | -2.6  [-4.29, -1.08] | 15 | -3.37  [-3.74, -3] | 32 | 0.26  [-0.16, 0.68] |
| CK.R | 405 | 36 | 1.05  [1, 1.1] | 0.9  [0.88, 0.91] | <0.001 | 0.4 | 0.55  [0.31, 0.79] | 17 | 1.33  [0.7, 1.95] | 4.6 | 0.75  [0.64, 0.85] | 9.1 | 0.96  [0.72, 1.2] |
| CK.LY30 | 86 | 17 | 1.01  [0.91, 1.1] | 0.91  [0.87, 0.94] | <0.001 | 0 | 0.48  [-0.12, 1.08] | 22 | 0.6  [-1.22, 2.41] | 0 | 0.48  [-0.12, 1.08] | 2.6 | 0.49  [0, 0.98] |
| CRT.MA | 394 | 0 | 0.93  [0.89, 0.97] | 0.93  [0.92, 0.95] | <0.001 | 40 | -0.71  [-1.54, 0.12] | 75 | -3.16  [-3.64, -2.67] | 52 | -1.55  [-1.98, -1.11] | 70 | -2.81  [-3.15, -2.47] |
| CRT.MA vs. CK.MA | 336 | 0 | 1.06  [0.99, 1.12] | 0.86  [0.83, 0.89] | <0.001 | 40 | -5.31  [-6.95, -3.66] | 75 | -3.31  [-4.12, -2.51] | 52 | -4.62  [-5.51, -3.73] | 70 | -3.6  [-4.13, -3.06] |

AMR, analytical measurement range; CFF.MA, citrated functional fibrinogen maximum amplitude; CI, confidence interval; CK.LY30, citrated kaolin clot lysis at 30 minutes; CK.R, citrated kaolin reaction time; CRT.MA, citrated RapidTEG™ maximum amplitude; NRR, normal reference range

**Supplemental Table 2: Analysis of Within Device Variability for the TEG® 5000 Hemostasis Analyzer**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Assay** | **N** | **Spike** | **Slope**  **ß [95% CI]** | **Correlation ƿ [95% CI]** | **AMR Point 1** | **AMR Bias 1** | **AMR Point 2** | **AMR Bias 2** | **NRR Point 1** | **Bias at NRR Point 1** | **NRR Point 2** | **Ref Bias 2** |
| CFF.MA | 424 | 0 | 0.99  [0.96, 1.01] | 0.97  [0.96, 0.97] | 4 | 0.17  [-0.2, 0.65] | 52 | -0.33  [-1.07, 0.24] | 15 | 0.06  [-0.1, 0.29] | 32 | -0.12  [-0.4, 0.1] |
| CK.R | 425 | 0 | 0.99  [0.97, 1.01] | 0.99  [0.98, 0.99] | 0.4 | 0.05  [-0.02, 0.12] | 17 | -0.11  [-0.31, 0.09] | 4.6 | 0.01  [-0.01, 0.03] | 9.1 | -0.04  [-0.11, 0.04] |
| CK.LY30 | 81 | 0 | 1.32  [1.03, 1.6] | 0.71  [0.59, 0.81] | 0 | -0.72  [-1.84, 0.4] | 22 | 6.22  [0.54, 11.9] | 0 | -0.72  [-1.84, 0.4] | 2.6 | 0.1  [-0.74, 0.94] |
| CRT.MA | 413 | 0 | 0.95  [0.91, 1] | 0.9  [0.88, 0.92] | 40 | 1.17  [0.12, 2.22] | 75 | -0.43  [-1.06, 0.2] | 52 | 0.62  [0.07, 1.18] | 70 | -0.2  [-0.65, 0.25] |
| CRT.MA vs. CK.MA | 406 | 0 | 1.12  [1.03, 1.2] | 0.78  [0.74, 0.81] | 40 | -4.09  [-6.25, -1.93] | 75 | -0.03  [-1.14, 1.07] | 52 | -2.7  [-3.86, -1.54] | 69 | -0.73  [-1.41, -0.05] |

AMR, analytical measurement range; CFF.MA, citrated functional fibrinogen maximum amplitude; CI, confidence interval; CK.LY30, citrated kaolin clot lysis at 30 minutes; CK.R, citrated kaolin reaction time; CRT.MA, citrated RapidTEG™ maximum amplitude; NRR, normal reference range

**Supplemental Table 3: Analysis of Within Device Variability for the TEG® 6s Hemostasis Analyzer**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Assay** | **N** | **Spike** | **Slope**  **ß [95% CI]** | **Correlation ƿ [95% CI]** | **AMR Point 1** | **AMR Bias 1** | **AMR Point 2** | **AMR Bias 2** | **NRR Point 1** | **Bias at NRR Point 1** | **NRR Point 2** | **Ref Bias 2** |
| CFF.MA | 424 | 0 | 1  [0.98, 1.01] | 0.99  [0.99, 0.99] | 4 | 0  [-0.12, 0.27] | 52 | 0  [-0.66, 0.31] | 15 | 0  [-0.02, 0.1] | 32 | 0  [-0.28, 0.14] |
| CK.R | 425 | 0 | 0.96  [0.92, 1.01] | 0.9  [0.87, 0.91] | 0.4 | 0.17  [-0.06, 0.4] | 17 | -0.43  [-0.98, 0.11] | 4.6 | 0.01  [-0.06, 0.09] | 9.1 | -0.15  [-0.34, 0.04] |
| CK.LY30 | 81 | 0 | 1.04  [0.92, 1.17] | 0.88  [0.82, 0.92] | 0 | -0.47  [-0.97, 0.03] | 22 | 0.47  [-1.97, 2.91] | 0 | -0.47  [-0.97, 0.03] | 2.6 | -0.36  [-0.7, -0.03] |
| CRT.MA | 413 | 0 | 1  [0.98, 1.02] | 0.99  [0.98, 0.99] | 40 | 0.06  [-0.29, 0.4] | 75 | 0.04  [-0.21, 0.3] | 52 | 0.05  [-0.11, 0.22] | 70 | 0.05  [-0.14, 0.23] |
| CRT.MA vs. CK.MA | 406 | 0 | 1.12  [1.09, 1.16] | 0.95  [0.94, 0.96] | 40 | -1.86  [-2.6, -1.11] | 75 | 2.47  [1.89, 3.06] | 52 | -0.37  [-0.71, -0.03] | 69 | 1.73  [1.34, 2.11] |

AMR, analytical measurement range; CFF.MA, citrated functional fibrinogen maximum amplitude; CI, confidence interval; CK.LY30, citrated kaolin clot lysis at 30 minutes; CK.R, citrated kaolin reaction time; CRT.MA, citrated RapidTEG™ maximum amplitude; NRR, normal reference range